10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
French biotech Transgene has signed a series of agreements with China’s Tasly Biopharmaceuticals involving T601 and T101, two immunotherapeutics developed by the Transgene-Tasly joint venture 3 in China. 11 July 2018
US pharma major Bristol-Myers Squibb has scored an approval in a third tumor type with the combination of its two immuno-oncology drugs, Opdivo (nivolumab) and Yervoy (ipilimumab). 11 July 2018
US biotech Advaxis closed 8% down on Tuesday after feedback from the European Medicines Agency (EMA) led the company to announce the withdrawal of its conditional Marketing Authorization Application (MAA) for axalimogene filolisbac to treat metastatic cervical cancer in patients who progress beyond first-line therapy. 11 July 2018
The announcement on January 22 this year that US biotech firms BioCryst Pharmaceuticals and Idera Pharmaceuticals were merging did not go down well with investors, with their shares plunging by as much as 12% and 28%, respectively. 11 July 2018
In March 2018, Celgene announced its intention to co-develop and co-market bb2121, a bluebird bio CAR-T cell therapy for relapsed multiple myeloma. In conversation with The Pharma Letter, Tuomo Pätsi, worldwide president for hematology and oncology markets, makes a strong case for the drug. 11 July 2018
Sanofi Genzyme says that it is disappointed with the recent recommendation by the Canadian Agency for Drugs and Technologies in Health (CADTH) to not reimburse Dupixent (dupilumab), one of the most important recent pharmacological innovations for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD). 10 July 2018
Starpharma just announced its product VivaGel (astodrimer sodium) BV’s New Drugs Application (NDA) has advanced to the next stage of review by the US Food and Drug Administration. 10 July 2018
Results from a Phase III, randomized, double-blind, multi-center clinical study (BELIEVE) showed that luspatercept achieved a highly statistically-significant improvement in the primary endpoint of erythroid response, adding to earlier positive data a couple of weeks ago. 10 July 2018
German immunotherapeutics specialist BioNTech has inked a deal with RNA therapy specialist Genevant to guarantee further cooperation between the two on fighting rare diseases. 10 July 2018
France’s TxCell announced late Monday that it has exercised its exclusive option to in-license the intellectual property rights of one of its academic partners, the University of British Columbia (UBC), onto the HLA-A2 CAR-Treg program. 10 July 2018
San Diego-based Regulus Therapeutics, a microRNA specialist biotech, saw its share price collapse on Thursday following news of an imminent restructuring. 9 July 2018
When Seattle Genetics announced it had bought exclusive global rights to an an exciting new antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), shares in the candidate’s developer shot up by a third. 9 July 2018
Shares of Australian biotech firm Benitec Biopharma more than doubled after the company announced a lucrative licensing deal for a rare genetic disorder affecting the muscles of the upper eyelids and the throat with USA-based Axovant Sciences. 9 July 2018
NHS England has approved the reimbursement of Hemlibra (emicizumab) for the prevention of bleeding episodes in adults and children with hemophilia A who have factor VIII inhibitors, according to the drug’s marketers. 7 July 2018
Actelion, which is now part of US healthcare giant Johnson & Johnson, has announced that Uptravi (selexipag) will not be funded on the National Health Service (NHS) in England, meaning patients with life-limiting disease, pulmonary arterial hypertension (PAH), are forced to continue to wait for access. 7 July 2018
There was good news for US pharma major Bristol-Myers Squibb yesterday, with an expanded approval for its already blockbuster blood cancer drug Sprycel (dasatinib) in Europe. 6 July 2018
A new industry report highlights the importance of introducing novel technologies early in the cell line development and production processes. 6 July 2018
Japan’s Takeda Pharmaceutical and TiGenix have announced that at the end of the second acceptance period, Takeda will hold over 96% of all ordinary shares of the Belgian biotech. 6 July 2018
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024